After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. Insiders, especially beneficial owners, have been showing their love as well, and the largest insider purchases in the past week or so have largely been in biotech stocks.
Let’s take a quick look at all the most notable transactions of the past week or so.
This post originally appeared at 24/7 Wall St.